All In Biotech

Drug Trial Radar · NCT07294534

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

An Open-Label, Randomized, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87 (HER2 ADC) in Combination With HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) or Pertuzumab vs. TCbHP in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 817 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

817

Planned (sponsor's estimate)

Start

Jan 27, 2026

Primary completion

Sep 30, 2028

Study completion Feb 1, 2030

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Dec 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.

Conditions

  • HER2 + Breast Cancer

Interventions

  • HLX87+HX22Drug

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2

  • HLX87 + PertuzumabDrug

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan.

  • TCbHPDrug

    Docetaxel +Carboplatin+Trastuzumab+Pertuzumab+

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • Total pathologic complete response (tpCR) rateTime frame: up to 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.